Detection and Prediction of Clinically Significant Pneumothorax After Image-guided Transthoracic Lung Biopsy
Launched by CHINESE UNIVERSITY OF HONG KONG · Aug 17, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a chest X-ray (CXR) taken four hours after a lung biopsy can help doctors predict whether a patient will develop a significant pneumothorax, which is an air leak that can cause lung problems. The researchers believe that if the CXR shows no pneumothorax at four hours, it is likely that the patient will not have any serious issues by the next day. This information could help doctors determine if it's safe for patients to go home on the same day after their biopsy.
To participate in the study, patients must be scheduled for a lung biopsy that uses imaging guidance, such as ultrasound or CT scans, and they need to be able to give their consent to join the trial. The study is only looking for patients who do not have certain health conditions that might complicate the procedure. Participants will have chest X-rays taken at different times, and their results will help improve understanding of patient safety after lung biopsies. This could lead to better care and quicker recoveries for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients whose image-guided TTLB, including ultrasound or CT-guided, is arranged for diagnostic purposes
- • Patients who are able to sign written informed consent to participate in the study
- Exclusion Criteria:
- • Patients with resolution of lung lesion prior to the scheduled image-guided TTLB
- • Patients have active exacerbation of underlying diseases causing unstable respiratory conditions (e.g. exacerbation of COPD, pneumonia) which would lower the threshold for invasive interventions for iatrogenic pneumothorax
- • Patients with psychiatric disease or cognitive impairment that may limit their ability to understand or give consent to the study
- • Patients who decline to join the study
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
David SC Hui, MD
Study Director
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported